NCT05076006View on ClinicalTrials.gov

Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

May 19, 2021

Primary Completion Date

September 30, 2023

Study Completion Date

September 30, 2023

Conditions
Cicatricial Alopecia
Interventions
DRUG

PF-06700841

Active study drug

DRUG

Placebo

placebo comparator

Trial Locations (1)

10029

Icahn School of Medicine at Mount Sinai, New York

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Emma Guttman

OTHER

NCT05076006 - Dual JAK1/TYK2 Inhibitor for Cicatricial Alopecia | Biotech Hunter | Biotech Hunter